AstraZeneca said Thursday it would buy 55% of privately held biotech firm Acerta Pharma for $4 billion to bolster the UK pharmaceutical giant’s blood cancer treatment portfolio.
The latest deal caps an intense period of deal making for the UK drug maker as it races to refill its drug portfolio.
Setup a free account to get access to this article (no credit card required).
View Full ArticleMani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports
Get articles and insights from our weekly newsletter.
By entering your email, you agree to our Terms of Service and Privacy Policy.
